Targeted inhibition of mammalian target of rapamycin (mTOR) enhances radiosensitivity in pancreatic carcinoma cells

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 149-159

  Dai, Zhi Jun ^a   Gao, Jie ^a   Kang, Hua Feng ^a   Ma, Yu Guang ^a   Ma, Xiao Bin ^a   Lu, Wang Feng ^a   Lin, Shuai ^a   Ma, Hong Bing ^a   Wang, Xi Jing ^a   Wu, Wen Ying ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

mTOR; Pancreatic carcinoma; Radiation; Rapamycin

Indexed keywords

ABCC4 PROTEIN; COMPLEMENTARY DNA; CYCLINE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN DDB1; RAD51 PROTEIN; RAPAMYCIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; XRCC5 PROTEIN; TARGET OF RAPAMYCIN KINASE;

ABCC4 GENE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CARCINOMA CELL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLINE GENE; DDB1 GENE; DNA MICROARRAY; DOWN REGULATION; DRUG EFFECT; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; PANCREAS CARCINOMA; PROTEIN EXPRESSION; RAD51 GENE; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; S PHASE CELL CYCLE CHECKPOINT; TUMOR GENE; UPREGULATION; X IRRADIATION; XRCC5 GENE; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; PANCREATIC NEOPLASMS; PATHOLOGY; RADIATION RESPONSE; RADIATION TOLERANCE; TUMOR CELL LINE;

AUTOPHAGY; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; PANCREATIC NEOPLASMS; RADIATION TOLERANCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84875411554     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S42390     Document Type: Article

References (56)

1. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7(3):163-172.
2. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17): 1605-1617.
3. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607-620.
4. Dumont FJ, Bischoff P. Disrupting the mTOR signaling network as a potential strategy for the enhancement of cancer radiotherapy. Curr Cancer Drug Targets. 2012;12(8):899-924.
5. Beuvink I, Boulay A, Fumagalli S. The mTOR inhibitor RAD001sensi-tizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 2005;120(6):747-759.
6. Mabuchi S, Altomare DA, Cheung M. RAD001inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res. 2007;13(14): 4261-4270.
7. Houghton PJ, Morton CL, Gorlick R. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther. 2010;9(1):101-112.
8. Morris RE. Rapamycins: Antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev. 1992;6(1):39-87.
9. Svirshchevskaya EV, Mariotti J, Wright MH. Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity. BMC Cancer. 2008;8:176.
10. Wu Q, Kiguchi K, Kawamoto T. Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Res. 2007;67(8):3794-3800.
11. Butzal M, Loges S, Schweizer M. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp Cell Res. 2004;300(1):65-71.
12. Morikawa Y, Koike H, Sekine Y. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation. Biochem Biophys Res Commun. 2012;419(3):584-589.
13. Li R, Wang R, Zhai R, Dong Z. Targeted inhibition of mammalian target of rapamycin (mTOR) signaling pathway inhibits proliferation and induces apoptosis of laryngeal carcinoma cells in vitro. Tumori. 2011;97(6):781-786.
14. Di Paolo S, Teutonico A, Ranieri E, Gesualdo L, Schena PF. Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma. Am J Kidney Dis. 2007;49(3):462-470.
15. Guba M, von Breitenbuch P, Steinbauer M. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8(2):128-135.
16. Albert JM, Kim KW, Cao C, Lu B. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther. 2006;5(5):1183-1189.
17. No M, Choi EJ, Kim IA. Targeting HER2 signaling pathway for radiosensitization: alternative strategy for therapeutic resistance. Cancer Biol Ther. 2009;8(24):2351-2361.
18. Cao C, Subhawong T, Albert JM. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res. 2006;66(20):10040-10047.
19. Nagata Y, Takahashi A, Ohnishi K. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53gene status. Int J Onco. 2010;37(4):1001-1010.
20. Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN. Inhibition of the mammalian target of rapamycin sen-sitizes U87 xenografts to fractionated radiation therapy. Cancer Res. 2002;62(24):7291-7297.
21. Dai ZJ, Gao J, Ma XB. Up-regulation of hypoxia inducible factor-1α by cobalt chloride correlates with proliferation and apoptosis in PC-2cells. J Exp Clin Cancer Res. 2012;31:28.
22. Liang B, Kong D, Liu Y. Autophagy inhibition plays the synergetic killing roles with radiation in the multi-drug resistant SKVCR ovarian cancer cells. Radiat Oncol. 2012;7:213.
23. Dai ZJ, Gao J, Ma XB. Antitumor effects of rapamycin in pancreatic cancer cells by inducing apoptosis and autophagy. Int J Mol Sci. 2012;14(1):273-285.
24. Zhang B, Wang Y, Pang X. Enhanced radiosensitivity of EC109cells by inhibition of HDAC1 expression. Med Oncol. 2012;29(1):340-348.
25. Zsippai A, Szabó DR, Tömböl Z. Effects of mitotane on gene expression in the adrenocortical cell line NCI-H295R: a microarray study. Pharmacogenomics. 2012;13(12):1351-1361.
26. Guan HT, Xue XH, Dai ZJ, Wang XJ, Li A, Qin ZY. Down-regulation of survivin expression by small interfering RNA induces pancreatic cancer cell apoptosis and enhances its radiosensitivity. World J Gastroenterol. 2006;12(18):2901-2907.
27. Vo K, Amarasinghe B, Washington K, Gonzalez A, Berlin J, Dang TP. Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation. Mol Cancer. 2011;10:138.
28. Shen Y, Wang X, Xia W. Antiproliferative and overadditive effects of rapamycin and FTY720in pancreatic cancer cells in vitro. Transplant Proc. 2008;40(5):1727-1733.
29. Garrido-Laguna I, Tan AC, Uson M. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer. 2010;103(5):649-655.
30. Shafer A, Zhou C, Gehrig PA, Boggess JF, Bae-Jump VL. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. Int J Cancer. 2010;126(5):1144-1154.
31. Bjelogrlí SK, Srdí T, Radulović S. Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer. J BUON. 2006;11(3):267-276.
32. Saito K, Matsumoto S, Yasui H. Longitudinal imaging studies of tumor microenvironment in mice treated with the mTOR inhibitor rapamycin. PLoS ONE. 2012;7(11):e49456.
33. Mauceri HJ, Sutton HG, Darga TE. Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer. Oncol Rep. 2012;27(5):1625-1629.
34. Myers AL, Orr WS, Denbo JW. Rapamycin-induced tumor vasculature remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation. J Pediatr Surg. 2012;47(1):183-189.
35. Kuwahara Y, Oikawa T, Ochiai Y. Enhancement of autophagy is a potential modality for tumors refractory to radiotherapy. Cell Death Dis. 2011;2:e177.
36. Wilson EN, Bristol ML, Di X. A switch between cytoprotective and cytotoxic autophagy in the radiosensitization of breast tumor cells by chloroquine and vitamin D. Horm Cancer. 2011;2(5):272-285.
37. Gewirtz DA. Autophagy, senescence and tumor dormancy in cancer therapy. Autophagy. 2009;5(8):1232-1234.
38. Kim KW, Hwang M, Moretti L, Jaboin JJ, Cha YI, Lu B. Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer. Autophagy. 2008;4(5):659-668.
39. Eum KH, Lee M. Targeting the autophagy pathway using ectopic expres-sion of Beclin 1in combination with rapamycin in drug-resistant v-Haras-transformed NIH 3T3cells. Mol Cells. 2011;31(3):231-238.
40. Biederbick A, Kern HF, Elsässer HP. Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vacuoles. Eur J Cell Biol. 1995;66(1):3-14.
41. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(4):928-942.
42. Pauwels B, Wouters A, Peeters M, Vermorken JB, Lardon F. Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation. Future Oncol. 2010;6(9):1485-1496.
43. Ree AH, Stokke T, Bratland A. DNA damage responses in cell cycle G2 phase and mitosis-tracking and targeting. Anticancer Res. 2006;26(3A):1909-1916.
44. Choi EJ, Ryu YK, Kim SY. Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response. Mol Cancer Res. 2010;8(7): 1027-1036.
45. Schiewer MJ, Den R, Hoang DT. mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer. Endocr Relat Cancer. 2012;19(1):1-12.
46. Lee SM, Li ML, Tse YC. Paeoniae Radix, a Chinese herbal extract, inhibit hepatoma cells growth by inducing apoptosis in a p53 independent pathway. Life Sci. 2002;71(19):2267-2277.
47. Yin X, Zhou J, Jie C, Xing D, Zhang Y. Anticancer activity and mechanism of Scutellaria barbata extract on human lung cancer cell line A549. Life Sci. 2004;75(18):2233-2244.
48. Wang F, Tan W, Guo D, Zhu X, Qian K, He S. Altered expression of signaling genes in Jurkat cells upon FTY720 induced apoptosis. Int J Mol Sci. 2010;11(9):3087-3105.
49. Karagiannis TC, El-Osta A. Double-strand breaks: signaling pathways and repair mechanisms. Cell Mol Life Sci. 2004;61(17): 2137-2147.
50. Choudhury A, Cuddihy A, Bristow RG. Radiation and new molecular agents part I: targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin Radiat Oncol. 2006;16(1):51-58.
51. Jenner TJ, Fulford J, O'Neill P. Contribution of base lesions to radiation-induced clustered DNA damage: implication for models of radiation response. Radiat Res. 2001;156(5 Pt 2):590-593.
52. Taccioli GE, Gottlieb TM, Blunt T. Ku80: product of the XRCC5 gene and its roles in DNA repair and V(D)J recombination. Science. 1994; 265(5177):1442-1445.
53. Bryntesson F, Regan JC, Jeggo PA, Taccioli GE, Hubank M. Analysis of gene transcription in cells lacking DNA-PK activity. Radiat Res. 2001;156(2):167-176.
54. Evans JW, Liu XF, Kirchgessner CU, Brown JM. Induction and repair of chromosome aberrations in scid cells measured by premature chromosome condensation. Radiat Res. 1996;145(1):39-46.
55. Hashiguchi K, Matsumoto Y, Yasui A. Recruitment of DNA repair synthesis machinery to sites of DNA damage/repair in living human cells. Nucleic Acids Res. 2007;35(9):2913-2923.
56. Lee BJ, Wang SG, Roh HJ, Goh EK, Chon KM, Park DY. Changes in expression of p53, proliferating cell nuclear antigen and bcl-2 in recurrent laryngeal cancer after radiotherapy. J Laryngol Otol. 2006; 120(7):579-582.